Schroder Investment Management Group
ITCI

Schroder Investment Management Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Schroder Investment Management Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-743,230
Closed -$62M – 1273
2024
Q4 		$62M Sell
743,230
-180,941
-20% -$14.9M 0.06% 257
2024
Q3 		$67.7M Buy
924,171
+172,281
+23% +$12.9M 0.07% 231
2024
Q2 		$51.5M Buy
751,890
+133,502
+22% +$9.26M 0.06% 276
2024
Q1 		$42.8M Sell
618,388
-161,435
-21% -$11.1M 0.05% 325
2023
Q4 		$55.9M Buy
779,823
+209,331
+37% +$12M 0.07% 253
2023
Q3 		$29.7M Sell
570,492
-149,419
-21% -$8.7M 0.04% 366
2023
Q2 		$45.6M Sell
719,911
-226,074
-24% -$14.1M 0.07% 298
2023
Q1 		$51.2M Buy
945,985
+82,024
+9% +$3.97M 0.08% 264
2022
Q4 		$45.7M Sell
863,961
-13,576
-2% -$680K 0.07% 281
2022
Q3 		$40.8M Buy
877,537
+37,021
+4% +$1.93M 0.07% 289
2022
Q2 		$49M Sell
840,516
-143,397
-15% -$8.13M 0.07% 261
2022
Q1 		$59.4M Sell
983,913
-195,926
-17% -$10.2M 0.08% 248
2021
Q4 		$61.8M Buy
1,179,839
+30,498
+3% +$1.28M 0.08% 249
2021
Q3 		$42.8M Sell
1,149,341
-155,849
-12% -$5.42M 0.07% 309
2021
Q2 		$53.3M Sell
1,305,190
-17,806
-1% -$658K 0.07% 294
2021
Q1 		$44.9M Buy
1,322,996
+9,970
+0.8% +$346K 0.06% 328
2020
Q4 		$41.8M Buy
1,313,026
+313,129
+31% +$8.23M 0.06% 309
2020
Q3 		$23.8M Sell
999,897
-119,645
-11% -$2.73M 0.04% 390
2020
Q2 		$28.7M Buy
1,119,542
+1,709
+0.2% +$34.6K 0.05% 338
2020
Q1 		$17.3M Buy
1,117,833
+364,938
+48% +$7.93M 0.04% 403
2019
Q4 		$25.8M Sell
752,895
-675,656
-47% -$8.11M 0.04% 433
2019
Q3 		$10.7M Sell
1,428,551
-1,918
-0.1% -$18.4K 0.02% 604
2019
Q2 		$18.6M Buy
1,430,469
+75,757
+6% +$972K 0.03% 461
2019
Q1 		$16.5M Buy
1,354,712
+197,356
+17% +$2.52M 0.03% 498
2018
Q4 		$13.2K Sell
1,157,356
-43,550
-4% -$703K 0.02% 512
2018
Q3 		$26.1M Buy
1,200,906
+7,312
+0.6% +$153K 0.04% 433
2018
Q2 		$21.2M Buy
+1,193,594
New +$24.2M 0.04% 446

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Schroder Investment Management Group's ITCI Position: Q1 2025 in Review

Schroder Investment Management Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 743,230 shares — an estimated $62M sold.

Schroder Investment Management Group first reported a position in ITCI in Q2 2018 and held it in 27 quarters. The position peaked at $67.7M in Q3 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Schroder Investment Management Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Schroder Investment Management Group sold 743,230 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $62M.
  • Schroder Investment Management Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2018 and held it in 27 quarters.
  • Schroder Investment Management Group's Intra-Cellular Therapies Inc. position peaked at $67.7M in Q3 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Schroder Investment Management Group's 13F filing for Q1 2025, filed 13 May 2025.